Lucamont is commonly used for the sustained, long-term management of persistent symptoms associated with chronic asthma, for the relief of allergic rhinitis manifestations, and for the prophylaxis of breathing difficulties caused by physical exercise. It is applied across therapeutic domains where additional symptomatic support is needed to address symptoms related to heightened physiological activity. This treatment is relevant for easing symptoms associated with seasonal and perennial allergies, such as nasal congestion, runny nose, and sneezing, as well as respiratory symptoms like recurrent wheezing and chest tightness. The medication is generally relevant in conditions characterized by periods of heightened symptoms, helping patients cope more steadily with difficult episodes.

“This medication is applied in clinical settings that involve recurrent or episodic symptom patterns, providing supportive relief when symptoms interfere with routine activities.”

Quick Fact: Relief for Asthma and Allergy Symptoms

Condition Type	Symptom Focus	Therapeutic Benefit
Chronic Conditions	Persistent wheezing, chest tightness	May help maintain a sense of stability and contributes to easing distress.
Episodic Triggers	Exercise-induced breathing difficulty	Assists with maintaining functional stability when symptoms interfere with daily comfort.
Allergic Responses	Nasal congestion, rhinorrhea	Contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. NIH DailyMed Montelukast Prescribing Information

Eligibility Map: Who Can and Cannot Use Lucamont — Official Regulatory Information

---

Eligibility Scope

Classification	Status/Population
Populations for whom use is allowed	Adults and adolescents ge 15 years; Pediatric patients down to mathbf6 months (for specific uses); Patients with renal impairment (all degrees); Patients with mild-to-moderate hepatic impairment.
Populations for whom use is not recommended	Women who are nursing/breastfeeding (use only if clearly essential).
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance Montelukast or any excipients.
Age-related restrictions	Safety and effectiveness are not established in infants below mathbf6 months (for perennial allergic rhinitis) or mathbf12 months (for asthma).
Condition-specific restrictions	Lucamont is not indicated for the reversal of bronchospasm in acute asthma attacks. Use in severe hepatic impairment is not evaluated.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

• Contraindicated: Hypersensitivity.
• Not Indicated: Acute asthma/bronchospasm.
• Use Only if Clearly Essential: Pregnancy and Lactation.

Eligibility-context constraints (as defined in official documents):

• Use is restricted to maintenance treatment; it is contraindicated for abrupt substitution of corticosteroids.

---

Resulting Eligibility Structure

Official eligibility statements:

• Lucamont is contraindicated in patients with a known hypersensitivity to Montelukast or any excipients.
• It is not indicated for use in the reversal of bronchospasm during acute asthma attacks.
• Safety and effectiveness are not established in children below 6 months of age for specific uses.
• No dosage adjustment is required for patients with renal impairment or mild-to-moderate hepatic impairment.

Connection to the overall eligibility profile:

Regulatory documents define eligibility for Lucamont by strictly prohibiting its use in individuals with hypersensitivity and explicitly excluding its application for acute asthma exacerbations. Labels establish minimum age thresholds for various conditions and specify conditional use only when clearly essential for physiological states like pregnancy and lactation.

Lucamont Interactions with other medicines and products

This section details the formal interaction profile of Lucamont (Montelukast) as documented in official government regulatory information.

Documented Pharmacokinetic Interactions

Lucamont is processed by liver enzymes (CYP3A4, CYP2C8, and CYP2C9). This metabolism is the basis for several documented interactions:

• Increased Exposure: The potent enzyme inhibitor Gemfibrozil significantly increases the systemic exposure of Lucamont by approximately 4.4-fold. However, regulatory documents do not generally mandate a routine dosage adjustment based on this finding.
• Decreased Exposure: Strong enzyme inducers such as Rifampicin, Phenytoin, and Phenobarbital may potentially reduce the plasma concentration of Lucamont.

Interactions Without Clinically Significant Effect

Official studies have confirmed that co-administration of Lucamont does not result in clinically important pharmacokinetic interactions with widely used medicines, including Theophylline, Prednisone, Warfarin, Digoxin, and Oral Contraceptives.

Other Constraints and Considerations

Constraint Type	Details as Stated in Regulatory Documents
Prohibited Combinations	None are formally documented as contraindicated with other medicinal products.
Specific Precaution	Patients with known aspirin sensitivity must continue to avoid Aspirin or other NSAIDs while taking Lucamont.
Food Effect	A high-fat meal reduces the maximum concentration (Cmax) of the oral granule formulation by 35%.
Population Note	Caution is advised in children when co-administering CYP enzyme inducers. Mild-to-moderate hepatic impairment leads to a 41% higher mean exposure (AUC).

Selective Leukotriene Receptor Antagonism

Lucamont is classified as a leukotriene receptor antagonist that acts through highly selective binding to the Cysteinyl Leukotriene Type-1 ( CysLT1) receptor. This binding prevents CysLTs, such as Leukotriene D4 ( LTD4), from activating the receptor. The CysLT1 receptor is expressed on target cells, including airway smooth muscle and specific inflammatory cells. This mechanism initiates a suppression of the downstream signaling sequence normally triggered by the CysLT mediators.

---

Interruption of Inflammatory Cascades

The drug's interaction with the CysLT1 receptor results in the interruption of CysLT-mediated signaling cascades that influence specific physiological processes. This includes altering the CysLT-driven increase in vascular permeability and modulating the chemotaxis of eosinophils to relevant sites, thereby influencing upstream molecular steps within defined inflammatory cascades.

---

Modification of Physiological Tone

The resulting pathway antagonism leads to altered activity within CysLT-mediated signaling pathways. This modification results in attenuated CysLT-driven smooth muscle contraction and decreased CysLT-induced fluid extravasation and secretory activity within targeted physiological systems.

Lucamont, containing the active ingredient montelukast, is a leukotriene receptor antagonist used for the long-term management of asthma, the prevention of exercise-induced bronchoconstriction, and for the relief of symptoms of seasonal and perennial allergic rhinitis in specific patient populations. This medication is not a fast-acting rescue treatment and should not be used for acute asthma attacks; patients must always have appropriate rescue medication readily available.

Lucamont should be administered orally once daily. The timing of the dose depends on the indication:

• For Asthma and/or Perennial Allergic Rhinitis: Take the tablet once daily in the evening, with or without food. Consistent daily use is essential to maintain the control of chronic symptoms, even when the patient is asymptomatic.
• For Seasonal Allergic Rhinitis: The tablet is taken once daily, and the time of administration may be individualized to suit the patient's needs.
• For Prevention of Exercise-Induced Bronchoconstriction (EIB): A single dose should be taken at least two hours before exercise. Patients already taking a daily dose of Lucamont for asthma or allergies should not take an additional dose for EIB prevention. Do not exceed one dose within a 24-hour period.

Age Group (Asthma/Rhinitis)	Recommended Dose (Montelukast equivalent)	Dosing Schedule
Adults and Adolescents 15 years	10 mg Tablet	Once daily in the evening (Asthma) or once daily (Rhinitis)

If a dose is missed, patients should skip the missed dose and resume the regular dosing schedule; do not double the dose to compensate. Consult a healthcare provider before discontinuing treatment or reducing the dosage of any concomitant asthma therapy, such as inhaled corticosteroids.

Research evidence / Overview of studies for Lucamont

1. Evidence for Long-Term Maintenance of Chronic Asthma

Lucamont was studied for its role in the long-term control of asthma, a condition characterized by fluctuating or episodic manifestations. The primary clinical research was conducted using Randomized Controlled Trials (RCTs), where patients were monitored to evaluate specific measured outcomes like lung function measures (FEV1) and asthma symptom scores. Findings data show patterns related to measured changes during the study period. However, comparative evidence explores the magnitude of measured effect compared to that reported for inhaled corticosteroid treatments, suggesting a difference in measured outcomes. Research examined conditions involving heightened symptom activity, such as asthma associated with aspirin sensitivity.

2. Evidence for Prophylaxis of Exercise-Induced Breathing Difficulty

Research specifically explored the use of Lucamont in relation to episodic or acute changes in breathing that occur during physical activity. These studies used controlled exercise challenge protocols to monitor physiological strain by measuring a drop in a lung function outcome. Findings indicate measured changes in this drop in lung function when the study drug was used compared to controls. This evidence suggests that the observed pattern of attenuation, following a single administration, was typically confined to a 24-hour period. Therefore, research explored continuous administration over time.

3. Summary of Research Gaps and Remaining Uncertainties

Certain areas of uncertainty exist within the evidence landscape. Limited information for long-term outcomes regarding asthma control is a research gap, as many pivotal studies utilized follow-up durations that were limited to several weeks. Comparative evidence is lacking in some areas, particularly concerning how the measured effects compare against some widely available non-steroidal allergy treatments. Additionally, data for certain groups remain insufficient, with some subgroup findings being uncertain or inconsistent, especially in pre-school children experiencing episodic wheezing.

Key Studies & References

1. Montelukast versus inhaled corticosteroids for chronic asthma: an updated systematic review and meta-analysis
2. Montelukast in the treatment of seasonal and perennial allergic rhinitis

Common questions about Lucamont (FAQ)

---

Q: Is Lucamont the same kind of medicine as other treatments for this condition?

Lucamont is classified as a Leukotriene Receptor Antagonist (LTRA). Official product information indicates that this medicine works by blocking specific inflammatory substances called leukotrienes. This mechanism of action is different from other classes of respiratory treatments, such as inhaled corticosteroids or rapid-acting bronchodilators.

---

Q: Can Lucamont be taken with common over-the-counter pain relievers?

Regulatory documents note that Lucamont has no documented clinically significant interactions with many commonly used medicines. However, if a patient has a known sensitivity to aspirin, they must continue to avoid aspirin and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) while taking this medicine.

---

Q: What if Lucamont doesn't seem to be working for me after a few weeks?

Official guidance suggests that the desired effects on asthma control parameters usually begin within one day of starting the treatment. If a patient has concerns about effectiveness, regulatory guidance advises consulting a healthcare provider for review.

---

Q: Are there any long-term effects associated with taking Lucamont?

Regulatory bodies have issued prominent safety warnings regarding the potential for serious neuropsychiatric events. These include changes in mood and behavior, such as suicidal thoughts and actions. Official warnings highlight that patients taking the medicine should be monitored for these potential safety concerns.

---

Q: Is Lucamont safe to use during pregnancy, according to official classification?

According to official regulatory information, available data from published studies have not established a drug-associated risk of major birth defects. However, use during pregnancy is recommended only if a healthcare provider determines that it is clearly essential.

---

Q: Why is Lucamont sometimes used for a different purpose than its main one?

Lucamont is formally approved by regulatory bodies only for its documented indications: long-term maintenance of asthma, prevention of exercise-induced breathing difficulty, and relief of allergic rhinitis symptoms. Official guidance documents list specific indications, and the use of the medicine for purposes outside of these approved indications is not supported.

---

Q: Does the evidence suggest Lucamont is better for certain groups of people?

Studies and official documents indicate that the medicine's role in managing specific conditions, such as asthma associated with aspirin sensitivity, has been specifically explored in research. This suggests a documented use in certain patient subgroups.

---

Q: Can Lucamont interact with vitamins or herbal supplements?

Lucamont is processed in the liver by specific enzymes (CYP3A4, 2C8, 2C9). Regulatory documents state that potent inducers or inhibitors of these enzymes may affect the concentration of Lucamont. It is important that patients disclose all vitamins, herbal products, and supplements they take to their healthcare provider.

---

Q: What does 'contraindication' mean in relation to Lucamont?

A contraindication is a medical term used in official documents indicating that the medicine must not be used because the risks outweigh the benefits. For Lucamont, the only absolute contraindication is a known hypersensitivity, or allergy, to the active substance (montelukast) or any inactive ingredients.

---

Q: How does Lucamont work in simple terms?

Lucamont is classified as a leukotriene receptor antagonist. In simple terms, it works by blocking the effects of natural substances in the body called leukotrienes. These substances are known to cause swelling and narrowing of the airways, contributing to asthma and allergy symptoms.

---

Q: Are there known interactions between Lucamont and common allergy medications?

Official studies have not reported any clinically important interactions between Lucamont and widely used medications, such as Theophylline. There is no specific regulatory warning against using this medicine with common non-steroidal allergy medications (antihistamines).

---

Q: Is there any research on Lucamont and long-term quality of life?

Clinical studies used for drug approval primarily measure objective outcomes such as lung function and symptom scores. Official regulatory summaries do not typically list Quality of Life as a pivotal primary endpoint of these registration studies.

---

Q: What is the expected outcome of treatment with Lucamont?

The expected outcome of using Lucamont is the long-term control and maintenance of chronic airway inflammation. This prophylactic function is designed to continually reduce symptoms of asthma and allergic rhinitis and help prevent breathing difficulty caused by exercise.

---

Q: How quickly does Lucamont usually start to work?

Official product information indicates that the therapeutic effect on control parameters for asthma usually occurs within one day of beginning treatment. Lucamont is meant for long-term control and is not a fast-acting rescue medicine.

---

Q: Is it okay to drink alcohol while taking Lucamont?

There are no known direct, formal interactions between the active ingredient in Lucamont (montelukast) and alcohol. However, the medicine is processed by the liver, and patients should discuss alcohol intake with a healthcare provider due to the known need to monitor for potential liver problems.

---

Q: How long does Lucamont stay in your system?

According to official pharmacokinetic information, the mean plasma half-life of the active substance in adults is approximately 7.9 pm 1.9 hours. The half-life describes the time required for the amount of drug in the body to be reduced by half.

---

Q: Why do official documents mention studies about Lucamont and heart health?

Official regulatory documents list cardiovascular events, specifically palpitations, as a rare adverse reaction. Furthermore, healthcare providers are alerted to the potential for cardiac complications in very rare cases of systemic eosinophilia, which is a condition known as Churg-Strauss Syndrome.

---

Q: What is the typical duration of treatment with Lucamont?

Lucamont is designed for the long-term management and maintenance of chronic conditions. The length of treatment is not fixed, and official guidance confirms that patients typically maintain continuous use for as long as determined by a healthcare professional.

---

Q: Do I need special tests before starting Lucamont?

The official labeling does not typically mandate routine laboratory tests, such as blood work, before starting treatment. Due to the potential for rare liver injury, monitoring of liver enzyme levels is an area that may be considered in clinical practice.

---

Q: What if I take too much Lucamont?

Regulatory documents indicate that reported symptoms of an overdose may include stomach pain, sleepiness, thirst, headache, vomiting, and restlessness or agitation. There is no specific treatment for an overdose, and management is based on addressing the patient's symptoms.

---

Q: Is Lucamont a branded name or a generic name?

Lucamont contains the active ingredient Montelukast, which is the generic name for the compound. The medicine was originally marketed under the brand name Singulair.

---

Q: Are there any warnings about driving or operating machinery while taking Lucamont?

Official product information indicates that Lucamont is generally reported to have no or negligible influence on a person's ability to drive or use machines. However, caution is advised because rare reports of dizziness or drowsiness have occurred.

---

Q: Is it common to feel tired when starting Lucamont?

Official documents list tiredness and drowsiness (somnolence) as potential side effects of the medicine. This is classified as a less common or uncommon side effect according to regulatory classification tables.

---

Q: What should I do if I feel worse after starting Lucamont?

If new or worsening symptoms occur, or if new or worsening mood changes are observed, regulatory authorities state that the medicine must be discontinued immediately, and patients should seek immediate consultation with a healthcare provider.

---

Q: What kind of monitoring is typically done when a person is on Lucamont?

Regulatory authorities require patients and caregivers to be monitored for the occurrence of serious neuropsychiatric events. Official warnings advise that patients must contact a healthcare provider immediately if changes in behavior or mood occur.

---

Q: How is Lucamont eliminated from the body?

According to official pharmacokinetic documents, the active substance, Montelukast, and its breakdown products (metabolites) are eliminated almost entirely via the bile. They are then excreted from the body via the faeces.

---

Q: What regulatory bodies have approved Lucamont for use?

Regulatory approval for Lucamont (Montelukast) has been granted by government agencies worldwide. These include the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Therapeutic Goods Administration (TGA) in Australia.

---

Q: Can Lucamont be split or crushed?

Official documents state that non-chewable film-coated tablets must be swallowed whole and not chewed or crushed. Chewable tablets, however, are specifically designed to be chewed or sucked.

---

Q: What is the difference between a film-coated tablet and a chewable tablet?

Film-coated tablets are typically swallowed whole and are generally prescribed for older adolescents and adults. Chewable tablets are primarily for pediatric patients and, in some formulations, have specific requirements to be taken in relation to mealtimes.

Official Storage and Disposal Instructions

Storage Condition Requirements

The official label states that Lucamont must be stored below 25 C (or at Controlled Room Temperature up to 30 C in some regions).

Storage Factor	Regulatory Requirement
Temperature	Store below 25 C (or 30 C, depending on formulation).
Protection	Protect from both light and moisture.
Packaging	Keep the medicine in the original container (blister or bottle) to maintain protection.
Stability	If using an HDPE bottle pack, discard any unused product 30 days after first opening.

Handling and Disposal

Lucamont must be handled carefully to avoid exposure to moisture and light and should not be stored in environments prone to excessive heat. Any unused or expired medicine must be disposed of in accordance with local requirements. Disposal should utilize approved medicine take-back programs or local waste procedures, as the product is not typically listed for flushing.